Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 13 March 1987:
Vol. 235. no. 4794, pp. 1376 - 1379
DOI: 10.1126/science.2435003
Prev | Table of Contents | Next

Articles

Science, Vol 235, Issue 4794, 1376-1379
Copyright © 1987 by American Association for the Advancement of Science

articles

Ribavirin antagonizes the effect of azidothymidine on HIV replication

MW Vogt, KL Hartshorn, PA Furman, TC Chou, JA Fyfe, LA Coleman, C Crumpacker, RT Schooley, and MS Hirsch

Azidothymidine and ribavirin both inhibit replication of human immunodeficiency virus in vitro and show promise of clinical utility in patients infected with this virus. In this study, the possible interactions of these drugs were examined in vitro, and a reproducible antagonism between azidothymidine and ribavirin was found to occur under a variety of experimental conditions. The mechanism responsible for this antagonism appeared to be inhibition of azidothymidine phosphorylation by ribavirin. Because similar effects may occur in vivo, clinical trials of these two drugs in combination must be performed only under carefully controlled conditions.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Trends in the Treatment of Chronic Hepatitis C Virus Infection.
J. J. Kiser (2009)
Journal of Pharmacy Practice 22, 405-418
   Abstract »    PDF »
Coinfection with Hepatitis C Virus and Human Immunodeficiency Virus: Virological, Immunological, and Clinical Outcomes.
Y. Rotman and T. J. Liang (2009)
J. Virol. 83, 7366-7374
   Full Text »    PDF »
Debio 025, a Cyclophilin Binding Molecule, Is Highly Efficient in Clearing Hepatitis C Virus (HCV) Replicon-Containing Cells When Used Alone or in Combination with Specifically Targeted Antiviral Therapy for HCV (STAT-C) Inhibitors.
L. Coelmont, S. Kaptein, J. Paeshuyse, I. Vliegen, J.-M. Dumont, G. Vuagniaux, and J. Neyts (2009)
Antimicrob. Agents Chemother. 53, 967-976
   Abstract »    Full Text »    PDF »
Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methylcytidine, the active component of valopicitabine..
L. Coelmont, J. Paeshuyse, M. P. Windisch, E. De Clercq, R. Bartenschlager, and J. Neyts (2006)
Antimicrob. Agents Chemother. 50, 3444-3446
   Abstract »    Full Text »    PDF »
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies.
T.-C. Chou (2006)
Pharmacol. Rev. 58, 621-681
   Abstract »    Full Text »    PDF »
Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects..
S. Ramanathan, A. Cheng, A. Mittan, R. Ebrahimi, and B. P. Kearney (2006)
J. Clin. Pharmacol. 46, 559-566
   Abstract »    Full Text »    PDF »
MORBIDITY AND MORTALITY PROFILE OF HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS WITH AND WITHOUT HEPATITIS C CO-INFECTION.
A. M. MAYOR, M. A. GOMEZ, D. M. FERNANDEZ, E. RIOS-OLIVARES, J. C. THOMAS, and R. F. HUNTER (2006)
Am J Trop Med Hyg 74, 239-245
   Abstract »    Full Text »    PDF »
Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Results of a Randomized Clinical Study.
M. Rodriguez-Torres, F. J. Torriani, V. Soriano, M. J. Borucki, E. Lissen, M. Sulkowski, D. Dieterich, K. Wang, J.-M. Gries, P. G. Hoggard, et al. (2005)
Antimicrob. Agents Chemother. 49, 3997-4008
   Abstract »    Full Text »    PDF »
HCV/HIV-coinfection--is there a state of the art after APRICOT and RIBAVIC?.
S. Mauss and J. K. Rockstroh (2005)
J. Antimicrob. Chemother. 56, 615-618
   Abstract »    Full Text »    PDF »
In Vitro Combination of Amdoxovir and the Inosine Monophosphate Dehydrogenase Inhibitors Mycophenolic Acid and Ribavirin Demonstrates Potent Activity against Wild-Type and Drug-Resistant Variants of Human Immunodeficiency Virus Type 1.
K. Borroto-Esoda, F. Myrick, J. Feng, J. Jeffrey, and P. Furman (2004)
Antimicrob. Agents Chemother. 48, 4387-4394
   Abstract »    Full Text »    PDF »
Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons.
R. T. Chung, J. Andersen, P. Volberding, G. K. Robbins, T. Liu, K. E. Sherman, M. G. Peters, M. J. Koziel, A. K. Bhan, B. Alston, et al. (2004)
N. Engl. J. Med. 351, 451-459
   Abstract »    Full Text »    PDF »
Hepatitis C in the HIV-Infected Person.
M. S. Sulkowski and D. L. Thomas (2003)
Ann Intern Med 138, 197-207
   Abstract »    Full Text »    PDF »
Reciprocal Interaction of Human Immunodeficiency Virus and Hepatitis C Virus Infections.
K. E. Nelson and D. L. Thomas (2001)
Clin. Vaccine Immunol. 8, 867-870
   Full Text »    PDF »
Hepatitis C virus RNA dynamics during antiretroviral therapy.
R. Bruno, P. Sacchi, G. Filice, S. Yokozaki, J. Takamatsu, I. Nakano, Y. Katano, H. Toyoda, K. Hayashi, T. Hayakawa, et al. (2001)
Blood 97, 3318-3319
   Full Text »    PDF »
Management of the HIV-HCV coinfected patient.
D MUTIMER (2000)
Gut 47, 608-609
   Full Text »    PDF »
Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.
H Zylberberg, Y Benhamou, J L Lagneaux, A Landau, M-L Chaix, H Fontaine, M Bochet, T Poynard, C Katlama, G Pialoux, et al. (2000)
Gut 47, 694-697
   Abstract »    Full Text »    PDF »
Ribavirin Inhibits Viral-Induced Macrophage Production of TNF, IL-1, the Procoagulant fgl2 Prothrombinase and Preserves Th1 Cytokine Production But Inhibits Th2 Cytokine Response.
Q. Ning, D. Brown, J. Parodo, M. Cattral, R. Gorczynski, E. Cole, L. Fung, J. W. Ding, M. F. Liu, O. Rotstein, et al. (1998)
J. Immunol. 160, 3487-3493
   Abstract »    Full Text »    PDF »
Zidovudine: Five Years Later.
G. X. McLeod and S. M. Hammer (1992)
Ann Intern Med 117, 487-501
   Abstract »    PDF »
Molecular targets for AIDS therapy.
H Mitsuya, R Yarchoan, and S Broder (1990)
Science 249, 1533-1544
   Abstract »    PDF »
The Rocky Road to Effective Treatment of Human Immunodeficiency Virus (HIV) Infection.
M. S. Hirsch (1989)
Ann Intern Med 110, 1-3
   Abstract »    PDF »
Treatment of the Acquired Immunodeficiency Syndrome (AIDS) and AIDS-Related Complex with a Regimen of 3'-Azido-2',3'-Dideoxythymidine (Azidothymidine or Zidovudine) and Acyclovir: A Pilot Study.
A. SURBONE, R. YARCHOAN, N. MCATEE, M. R. BLUM, M. MAHA, J.-P. ALLAIN, R. V. THOMAS, H. MITSUYA, S. N. LEHRMAN, M. LEUTHER, et al. (1988)
Ann Intern Med 108, 534-540
   Abstract »    PDF »
Ribavirin Treatment of the Acquired Immunodeficiency Syndrome (AIDS) and the Acquired-Immunodeficiency-Syndrome-Related Complex (ARC) A Phase 1 Study Shows Transient Clinical Improvement Associated with Suppression of the Human Immunodeficiency Virus and Enhanced Lymphocyte Proliferation.
C. CRUMPACKER, W. HEAGY, G. BUBLEY, J. E. MONROE, R. FINBERG, S. HUSSEY, L. SCHNIPPER, D. LUCEY, T. H. LEE, M. F. MCLANE, et al. (1987)
Ann Intern Med 107, 664-674
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)